Paul Tudor Jones Cytom X Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

$15.5 Billion
Q1 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 43,865 shares of CTMX stock, worth $53,076. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,865

Previous 44,730 1.93%

Holding current value

$53,076

Previous $69,000 37.68%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.41 - $2.74 $1,219 - $2,370	-865 Reduced 1.93%	43,865 $95,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.88 $175,035 - $340,608	-118,267 Reduced 72.56%	44,730 $68,000
Q1 2022 May 16, 2022	BUY	$2.67 - $4.68 $435,201 - $762,825	162,997 New	162,997 $435,000
Q1 2021 May 17, 2021	SELL	$6.6 - $9.0 $342,361 - $466,857	-51,873 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$6.47 - $7.9 $304,529 - $371,837	-47,068 Reduced 47.57%	51,873 $340,000

Q3 2020 Nov 16, 2020	BUY	$6.55 - $8.83 $487,123 - $656,687	74,370 Added 302.67%	98,941 $658,000
Q2 2020 Aug 14, 2020	SELL	$7.4 - $14.64 $138,528 - $274,060	-18,720 Reduced 43.24%	24,571 $205,000
Q1 2020 May 15, 2020	SELL	$3.61 - $8.6 $128,111 - $305,196	-35,488 Reduced 45.05%	43,291 $332,000
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $407,287 - $701,920	78,779 New	78,779 $655,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

43.9M

Call Options Held

105K

Put Options Held

4.5K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $79.8M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account